Promoter CpG island methylation in colorectal cancer: Biology and clinical applications

Epigenomics: From Chromatin Biology to Therapeutics

Volumn , Issue , 2012, Pages 306-322

  Derks, Sarah ^a   van Engeland, Manon ^b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b MAASTRICHT UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84923426582     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511777271.028     Document Type: Chapter

References (118)

1. Agrelo, R., Cheng, W.H., Setien, F., et al. (2006). Epigenetic inactivation of the premature aging Werner syndrome gene in human cancer. Proceedings of the National Academy of Sciences USA, 103, 8822—8827.
2. Arnold, C. N., Goel, A., and Boland, C. R., (2003). Role of hMLH1 promoter hypermethylation in drug resistance to 5-fluorouracil in colorectal cancer cell lines. International Journal of Cancer, 106, 66—73.
3. Baba, Y., Nosho, K., Shima, K., et al. (2010). Hypomethylation of the IGF2 DMR in colorectal tumors, detected by bisulfite pyrosequencing, is associated with poor prognosis. Gastroenterology, 139, 1855—1864.
4. Baker, S. J., Fearon, E. R., Nigro, J. M., et al. (1989). Chromosome 17 deletions and p53 gene mutations in colorectal carcinomas. Science, 244, 217—221.
5. Barault, L., Charon-Barra, C., Jooste, V., et al. (2008). Hypermethylator phenotype in sporadic colon cancer: Study on a population-based series of 582 cases. Cancer Research, 68, 8541—8546.
6. Belshaw, N. J., Elliott, G. O., Williams, E. A., et al. (2004). Use of DNA from human stools to detect aberrant CpG island methylation of genes implicated in colorectal cancer. Cancer Epidemiology and Biomarkers Prevention, 13, 1495—1501.
7. Bird, A. (2002). DNA methylation patterns and epigenetic memory. Genes and Development, 16, 6—21.
8. Bos, J. L., Fearon, E. R., Hamilton, S. R., et al. (1987). Prevalence of ras gene mutations in human colorectal cancers. Nature, 327, 293—297.
9. Brenner, C., Deplus, R., Didelot, C., et al. (2005). Myc represses transcription through recruitment of DNA methyltransferase corepressor. EMBO Journal, 24, 336—346.
10. Chan, A. O., Broaddus, R. R., Houlihan, P. S., et al. (2002). CpG island methylation in aberrant crypt foci of the colorectum. American Journal of Pathology, 160, 1823—1830.
11. Chen, W.D., Han, Z. J., Skoletsky, J., et al. (2005). Detection in fecal DNA of colon cancer-specific methylation of the nonexpressed vimentin gene. Journal of the National Cancer Institute, 97, 1124—1132.
12. Christensen, B. C., Houseman, E. A., Marsit, C. J., et al. (2009). Aging and environmental exposures alter tissue-specific DNA methylation dependent upon CpG island context. PLoS Genetics, 5, e1000602.
13. Cunningham, J. M., Christensen, E. R., Tester, D. J., et al. (1998). Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Research, 58, 3455—3460.
14. Dahlin, A. M., Palmqvist, R., Henriksson, M. L., et al. (2010). The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status. Clinical Cancer Research, 16, 1845—1855.
15. Deng, G., Peng, E., Gum, J., et al. (2002). Methylation of hMLH1 promoter correlates with the gene silencing with a region-specific manner in colorectal cancer. British Journal of Cancer, 86, 574—579.
16. Derks, S., Postma, C., Moerkerk, P. T., et al. (2006). Promoter methylation precedes chromosomal alterations in colorectal cancer development. Cell Oncology, 28, 247—257.
17. Derks, S., Postma, C., Carvalho, B., et al. (2008). Integrated analysis of chromosomal, micro-satellite and epigenetic instability in colorectal cancer identifies specific associations between promoter methylation of pivotal tumour suppressor and DNA repair genes and specific chromosomal alterations. Carcinogenesis, 29, 434—439.
18. Devos, T., Tetzner, R., Model, F., et al. (2009). Circulating methylated SEPT9 DNA in plasma is a biomarker for colorectal cancer. Clinical Chemistry, 55, 1337—1346.
19. Di Croce, L., Raker, V. A., Corsaro, M., et al. (2002). Methyltransferase recruitment and DNA hypermethylation of target promoters by an oncogenic transcription factor. Science, 295, 1079—1082.
20. Di Nicolantonio, F., Martini, M., Molinari, F., et al. (2008). Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. Journal of Clinical Oncology, 26, 5705—5712.
21. Douglas, E. J., Fiegler, H., Rowan, A., et al. (2004). Array comparative genomic hybridization analysis of colorectal cancer cell lines and primary carcinomas. Cancer Research, 64, 4817—4825.
22. Duffy, M. J. (2001). Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful? Clinical Chemistry, 47, 624—630.
23. Easwaran, H. P., Van Neste, L., Cope, L., et al. (2010). Aberrant silencing of cancer-related genes by CpGhypermethylation occurs independently of their spatial organization in the nucleus. Cancer Research, 70, 8015—8024.
24. Ebert, M. P., Model, F., Mooney, S., et al. (2006). Aristaless-like homeobox-4 gene methylation is a potential marker for colorectal adenocarcinomas. Gastroenterology, 131, 1418—1430.
25. Esteller, M., Garcia-Foncillas, J., Andion, E., et al. (2000). Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. New England Journal of Medicine, 343, 1350—1354.
26. Esteller, M., Gonzalez, S., Risques, R. A., et al. (2001). K-ras and p16 aberrations confer poor prognosis in human colorectal cancer. Journal of Clinical Oncology, 19, 299—304.
27. Fearon, E. R. and Vogelstein, B. (1990). A genetic model for colorectal tumorigenesis. Cell, 61, 759—767.
28. Feltus, F. A., Lee, E. K., Costello, J. F., et al. (2003). Predicting aberrant CpG island methylation. Proceedings of the National Academy of Sciences USA, 100, 12253—12258.
29. Feltus, F. A., Lee, E. K., Costello, J. F., et al. (2006). DNA motifs associated with aberrant CpG island methylation. Genomics, 87, 572—579.
30. Ferracin, M., Gafa, R., Miotto, E., et al. (2008). The methylator phenotype in microsatellite stable colorectal cancers is characterized by a distinct gene expression profile. Journal of Pathology, 214, 594—602.
31. Fraga, M. F., Ballestar, E., Montoya, G., et al. (2003). The affinity of differentMBDproteins for a specific methylated locus depends on their intrinsic binding properties. Nucleic Acids Research, 31, 1765—1774.
32. Frattini, M., Gallino, G., Signoroni, S., et al. (2006). Quantitative analysis of plasma DNA in colorectal cancer patients: a novel prognostic tool. Annals of the New York Academy of Sciences, 1075, 185—190.
33. Frigola, J., Song, J., Stirzaker, C., et al. (2006). Epigenetic remodeling in colorectal cancer results in coordinate gene suppression across an entire chromosome band. Nature Genetics, 38, 540—549.
34. Gagnon, J. F., Bernard, O., Villeneuve, L., et al. (2006). Irinotecan inactivation ismodulated by epigenetic silencing ofUGT1A1 incolon cancer. Clinical Cancer Research, 12, 1850—1858.
35. Gardiner-Garden, M. and Frommer, M. (1987). CpG islands in vertebrate genomes. Journal of Molecular Biology, 196, 261—282.
36. Gatto, N. M., Frucht, H., Sundararajan, V., et al. (2003). Risk of perforation after colonoscopy and sigmoidoscopy: a population-based study. Journal of the National Cancer Institute, 95, 230—236.
37. Gazin, C., Wajapeyee, N., Gobeil, S., et al. (2007). An elaborate pathway required for Ras-mediated epigenetic silencing. Nature, 449, 1073—1077.
38. Glockner, S. C., Dhir, M., Yi, J. M., et al. (2009). Methylation of TFPI2 in stool DNA: a potential novel biomarker for the detection of colorectal cancer. Cancer Research, 69, 4691—4699.
39. Gonzalgo, M. L., Hayashida, T., Bender, C. M., et al. (1998). The role of DNA methylation in expression of the p19/p16 locus in human bladder cancer cell lines. Cancer Research, 58, 1245—1252.
40. Grady, W.M., Rajput, A., Lutterbaugh, J. D., et al. (2001). Detection of aberrantly methylated hMLH1 promoter DNA in the serum of patients with microsatellite unstable colon cancer. Cancer Research, 61, 900—902.
41. Hark, A. T., Schoenherr, C. J., Katz, D. J., et al. (2000). CTCF mediates methylation-sensitive enhancer-blocking activity at the H19/Igf2 locus. Nature, 405, 486—489.
42. Hawkins, N., Norrie, M., Cheong, K., et al. (2002). CpG island methylation in sporadic colorectal cancers and its relationship to microsatellite instability. Gastroenterology, 122, 1376—1387.
43. Hellebrekers, D. M., Lentjes, M. H., van den Bosch, S. M., et al. (2009). GATA4 and GATA5 are potential tumor suppressors and biomarkers in colorectal cancer. Clinical Cancer Research, 15, 3990—3997.
44. Herman, J. G. and Baylin, S. B., (2003). Gene silencing in cancer in association with promoter hypermethylation. New England Journal of Medicine, 349, 2042—2054.
45. Herman, J. G., Umar, A., Polyak, K., et al. (1998). Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proceedings of the National Academy of Sciences USA, 95, 6870—6875.
46. Hermsen, M., Postma, C., Baak, J., et al. (2002). Colorectal adenoma to carcinoma progression follows multiple pathways of chromosomal instability. Gastroenterology, 123, 1109—1019.
47. Hitchins, M. P., Lin, V. A., Buckle, A., et al. (2007). Epigenetic inactivation of a cluster of genes flanking MLH1 in microsatellite-unstable colorectal cancer. Cancer Research, 67, 9107—9116.
48. Hoque, M. O., Kim, M. S., Ostrow, K. L., et al. (2008). Genome-wide promoter analysis uncovers portions of the cancer methylome. Cancer Research, 68, 2661—2670.
49. Humphries, A. and Wright, N. A. (2008). Colonic crypt organization and tumorigenesis. Nature Reviews in Cancer, 8, 415—424.
50. Iacopetta, B., Grieu, F., Li, W., et al. (2006). APC gene methylation is inversely correlated with features of the CpG island methylator phenotype in colorectal cancer. International Journal of Cancer, 119, 2272—2278.
51. Iacopetta, B., Kawakami, K., and Watanabe, T. (2008). Predicting clinical outcome of 5-fluorouracil-based chemotherapy for colon cancer patients: is the CpG island methylator phenotype the 5-fluorouracil responsive subgroup? International Journal of Clinical Oncology, 13, 498—503.
52. Ibrahim, A. E., Arends, M. J., Silva, A. L., et al. (2010). Sequential DNA methylation changes are associated with DNMT3Boverexpression in colorectal neoplastic progression. Gut, 60, 499—508.
53. Imperiale, T. F., Ransohoff, D. F., Itzkowitz, S. H., et al. (2004). Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. New England Journal of Medicine, 351, 2704—2714.
54. Irizarry, R. A., Ladd-Acosta, C., Wen, B., et al. (2009). The human colon cancer methylome shows similar hypo-and hypermethylation at conserved tissue-specific CpG island shores. Nature Genetics, 41, 178—186.
55. Issa, J. P. (1999). Aging, DNA methylation and cancer. Critical Reviews in Oncology and Hematology, 32, 31—43.
56. Issa, J. P. (2000). The epigenetics of colorectal cancer. Annals of the New York Academy of Sciences, 910, 140—153; discussion 153—155.
57. Itzkowitz, S. H., Jandorf, L., Brand, R., et al. (2007). Improved fecal DNA test for colorectal cancer screening. Clinical Gastroenterology and Hepatology, 5, 111—117.
58. Itzkowitz, S., Brand, R., Jandorf, L., et al. (2008). A simplified, noninvasive stool DNA test for colorectal cancer detection. American Journal of Gastroenterology, 103, 2862—2870.
59. Karapetis, C. S., Khambata-Ford, S., Jonker, D. J., et al. (2008). K-ras mutations and benefit from cetuximab in advanced colorectal cancer. New England Journal of Medicine, 359, 1757—1765.
60. Kawakami, K., Matsunoki, A., Kaneko, M., et al. (2011). Long interspersed nuclear element-1 hypomethylation is a potential biomarker for the prediction of response to oral fluoropyrimidines in microsatellite stable and CpG island methylator phenotype-negative colorectal cancer. Cancer Science, 102, 166—174.
61. Kim, M. S., Louwagie, J., Carvalho, B., et al. (2009). PromoterDNAmethylation of oncostatin m receptor-beta as a novel diagnostic and therapeutic marker in colon cancer. PLoS One, 4, e6555.
62. Lee, B. B., Lee, E. J., Jung, E. H., et al. (2009). Aberrant methylation of APC, MGMT, RASSF2A, and Wif-1 genes in plasma as a biomarker for early detection of colorectal cancer. Clinical Cancer Research, 15, 6185—6191.
63. Lee, S., Cho, N. Y., Yoo, E. J., et al. (2008). CpG island methylator phenotype in colorectal cancers: comparison of the new and classic CpG island methylator phenotype marker panels. Archives of Pathology and Laboratory Medicine, 132, 1657—1665.
64. Lee, T. I., Jenner, R. G., Boyer, L. A., et al. (2006). Control of developmental regulators by Polycomb in human embryonic stem cells. Cell, 125, 301—313.
65. Leung, W.K., To, K. F., Man, E. P., et al. (2004). Detection of epigenetic changes in fecal DNA as a molecular screening test for colorectal cancer: a feasibility study. Clinical Chemistry, 50, 2179—2182.
66. Leung, W.K., To, K. F., Man, E. P., et al. (2005). Quantitative detection of promoter hyper-methylation in multiple genes in the serum of patients with colorectal cancer. American Journal of Gastroenterology, 100, 2274—2279.
67. Levin, B., Lieberman, D. A., McFarland, B., et al. (2008). Screening and Surveillance for the Early Detection of Colorectal Cancer and Adenomatous Polyps, 2008: A joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. CA Cancer Journal Clinic, 58, 130—160.
68. Li, M., Chen, W.D., Papadopoulos, N., et al. (2009). Sensitive digital quantification of DNA methylation in clinical samples. Nature Biotechnology, 27, 858—863.
69. Licchesi, J. D., Van Neste, L., Tiwari, V. K., et al. (2010). Transcriptional regulation of Wnt inhibitory factor-1 by Miz-1/c-Myc. Oncogene, 29, 5923—5934.
70. Lofton-Day, C., Model, F., Devos, T., et al. (2008). DNA methylation biomarkers for blood-based colorectal cancer screening. Clinical Chemistry, 54, 414—423.
71. Lujambio, A., Calin, G. A., Villanueva, A., et al. (2008). A microRNA DNA methylation signature for human cancer metastasis. Proceedings of the National Academy of Sciences USA, 105, 13 556—13 561.
72. Maeda, K., Kawakami, K., Ishida, Y., et al. (2003). Hypermethylation of the CDKN2A gene in colorectal cancer is associated with shorter survival. Oncology Reports, 10, 935—938.
73. Malkhosyan, S., Rampino, N., Yamamoto, H., et al. (1996). Frameshift mutator mutations. Nature, 382, 499—500.
74. Marshall, K. W., Mohr, S., Khettabi, F. E., et al. (2010). A blood-based biomarker panel for stratifying current risk for colorectal cancer. International Journal of Cancer, 126, 1177—1186.
75. McCabe, M. T., Lee, E. K., and Vertino, P. M. (2009). A multifactorial signature of DNA sequence and polycomb binding predicts aberrant CpG island methylation. Cancer Research, 69, 282—291.
76. McNeil, C. (2008). K-Ras mutations are changing practice in advanced colorectal cancer. Journal of the National Cancer Institute, 100, 1667—1669.
77. Melotte, V., Lentjes, M. H., van den Bosch, S. M., et al. (2009). N-Myc downstream-regulated gene 4 (NDRG4): a candidate tumor suppressor gene and potential biomarker for colorectal cancer. Journal of the National Cancer Institute, 101, 916—927.
78. Muller, H. M., Oberwalder, M., Fiegl, H., et al. (2004). Methylation changes in faecal DNA: a marker for colorectal cancer screening? Lancet, 363, 1283—1285.
79. Nakamura, Y., Nishisho, I., Kinzler, K. W., et al. (1991). Mutations of the adenomatous polyposis coli gene in familial polyposis coli patients and sporadic colorectal tumors. Princess Takamatsu Symposium, 22, 285—292.
80. Nosho, K., Irahara, N., Shima, K., et al. (2008). Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample. PLoS One, 3, e3698.
81. Ogino, S., Kawasaki, T., Kirkner, G. J., et al. (2006). CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associations with male sex and KRAS mutations. Journal of Molecular Diagnostics, 8, 582—588.
82. Ogino, S., Kawasaki, T., Kirkner, G. J., et al. (2007a). Evaluation of markers for CpG island methylator phenotype (CIMP) in colorectal cancer by a large population-based sample. Journal of Molecular Diagnostics, 9, 305—314.
83. Ogino, S., Kawasaki, T., Kirkner, G. J., et al. (2007b). Molecular correlates with MGMT promoter methylation and silencing support CpG island methylator phenotype-low (CIMP-low) in colorectal cancer. Gut, 56, 1564—1571.
84. Ogino, S., Meyerhardt, J. A., Kawasaki, T., et al. (2007c). CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma. Virchows Archives, 450, 529—537.
85. Ohm, J. E., McGarvey, K. M., Yu, X., et al. (2007). A stem cell-like chromatin pattern may predispose tumor suppressor genes toDNAhypermethylation and heritable silencing. Nature Genetics, 39, 237—242.
86. Park, J.H., Kim, N. S., Park, J. Y., et al. (2010). MGMT-535G>T polymorphism is associated with prognosis for patients with metastatic colorectal cancer treated with oxaliplatin-based chemotherapy. Journal of Cancer Research and Clinical Oncology, 136, 1135—1142.
87. Parkin, D. M., Bray, F., Ferlay, J., et al. (2005). Global cancer statistics, 2002. CA Cancer Journal for Clinicians, 55, 74—108.
88. Parsons, R., Myeroff, L. L., Liu, B., et al. (1995). Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Research, 55, 5548—5550.
89. Petko, Z., Ghiassi, M., Shuber, A., et al. (2005). Aberrantly methylated CDKN2A, MGMT, and MLH1 in colon polyps and in fecal DNA from patients with colorectal polyps. Clinical Cancer Research, 11, 1203—1209.
90. Popat, S., Hubner, R., and Houlston, R. S. (2005). Systematic review of microsatellite instability and colorectal cancer prognosis. Journal of Clinical Oncology, 23, 609—618.
91. Rajagopalan, H., Bardelli, A., Lengauer, C., et al. (2002). Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status. Nature, 418, 934.
92. Rampino, N., Yamamoto, H., Ionov, Y., et al. (1997). Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype. Science, 275, 967—969.
93. Rodriguez, J., Munoz, M., Vives, L., et al. (2008). Bivalent domains enforce transcriptional memory of DNA methylated genes in cancer cells. Proceedings of the National Academy of Sciences USA, 105, 19 809—19 814.
94. Samowitz, W.S., Albertsen, H., Herrick, J., et al. (2005). Evaluation of a large, population-based sample supports a CpG island methylator phenotype in colon cancer. Gastroenterology, 129, 837—845.
95. Samowitz, W.S., Slattery, M. L., Sweeney, C., et al. (2007). APC mutations and other genetic and epigenetic changes in colon cancer. Molecular Cancer Reserch, 5, 165—170.
96. Schlesinger, Y., Straussman, R., Keshet, I., et al. (2007). Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nature Genetics, 39, 232—236.
97. Schuebel, K. E., Chen, W., Cope, L., et al. (2007). Comparing the DNA hypermethylome with gene mutations in human colorectal cancer. PLoS Genetics, 3, 1709—1723.
98. Shen, L., Catalano, P. J., Benson, A. B., III et al. (2007). Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clinical Cancer Research, 13, 6093—6098.
99. Shima, K., Nosho, K., Baba, Y., et al. (2011). Prognostic significance of CDKN2A (p16) promoter methylation and loss of expression in 902 colorectal cancers: cohort study and literature review. International Journal of Cancer, 128, 1080—1094.
100. Souza, R. F., Appel, R., Yin, J., et al. (1996). Microsatellite instability in the insulin-like growth factor II receptor gene in gastrointestinal tumours. Nature Genetics, 14, 255—257.
101. Squazzo, S. L., O'Geen, H., Komashko, V. M., et al. (2006). Suz12 binds to silenced regions of the genome in a cell-type-specific manner. Genome Research, 16, 890—900.
102. Straussman, R., Nejman, D., Roberts, D., et al. (2009). Developmental programming of CpG island methylation profiles in the human genome. Nature Structural and Molecular Biology, 16, 564—571.
103. Tanaka, N., Huttenhower, C., Nosho, K., et al. (2010). Novel application of structural equation modeling to correlation structure analysis of CpG island methylation in colorectal cancer. American Journal of Pathology, 177, 2731—2740.
104. Tanzer, M., Balluff, B., Distler, J., et al. (2010). Performance of epigenetic markers SEPT9 and ALX4 in plasma for detection of colorectal precancerous lesions. PLoS One, 5, e9061.
105. Tiwari, V. K., McGarvey, K. M., Licchesi, J. D., et al. (2008). PcG proteins, DNA methylation, and gene repression by chromatin looping. PLoS Biology, 6, 2911—2927.
106. Toyota, M., Ahuja, N., Ohe-Toyota, M., et al. (1999). CpG island methylator phenotype in colorectal cancer. Proceedings of the National Academy of Sciences USA, 96, 8681—8686.
107. Toyota, M., Suzuki, H., Sasaki, Y., et al. (2008). Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. Cancer Research, 68, 4123—4132. van Engeland, M., Derks, S., Smits, K. M., et al. (2011). Colorectal cancer epigenetics: complex simplicity. Journal of Clinical Oncology, 29, 1382—1391. van Rijnsoever, M., Grieu, F., Elsaleh, H., et al. (2002). Characterization of colorectal cancers showing hypermethylation at multiple CpG islands. Gut, 51, 797—802.
108. Vire, E., Brenner, C., Deplus, R., et al. (2006). The Polycomb group protein EZH2 directly controls DNA methylation. Nature, 439, 871—874.
109. Warusavitarne, J. and Schnitzler, M. (2007). The role of chemotherapy in microsatellite unstable (MSI-H) colorectal cancer. International Journal of Colorectal Diseases, 22, 739—748.
110. Weber, M., Davies, J. J., Wittig, D., et al. (2005). Chromosome-wide and promoter-specific analyses identify sites of differential DNA methylation in normal and transformed human cells. Nature Genetics, 37, 853—862.
111. Weisenberger, D. J., Siegmund, K. D., Campan, M., et al. (2006). CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nature Genetics, 38, 787—793.
112. Weller, M., Stupp, R., Reifenberger, G., et al. (2010). MGMT promoter methylation in malignant gliomas: ready for personalized medicine? Nature Reviews in Neurology, 6, 39—51.
113. Wong, R. and Cunningham, D. (2008). Using predictive biomarkers to select patients with advanced colorectal cancer for treatment with epidermal growth factor receptor anti-bodies. Journal of Clinical Oncology, 26, 5668—5670.
114. Yamaguchi, S., Asao, T., Nakamura, J., et al. (2003). High frequency of DAP-kinase gene promoter methylation in colorectal cancer specimens and its identification in serum. Cancer Letters, 194, 99—105.
115. Yamakuchi, M., Ferlito, M., and Lowenstein, C. J. (2008). miR-34a repression of SIRT1 regulates apoptosis. Proceedings of the National Academy of Sciences USA, 105, 13 421—13 426.
116. Yoder, J. A., Soman, N. S., Verdine, G. L., et al. (1997). DNA (cytosine-5)-methyltransferases in mouse cells and tissues: studies with a mechanism-based probe. Journal of Molecular Biology, 270, 385—395.
117. Zhang, W., Bauer, M., Croner, R. S., et al. (2007). DNA stool test for colorectal cancer: hypermethylation of the secreted frizzled-related protein-1 gene. Diseases of Colon and Rectum, 50, 1618—1626; discussion 1626—1627.
118. Zinn, R. L., Pruitt, K., Eguchi, S., et al. (2007). hTERT is expressed in cancer cell lines despite promoter DNA methylation by preservation of unmethylated DNA and active chromatin around the transcription start site. Cancer Research, 67, 194—201.